Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Total deal value climbed to $135.7 billion for the full year in 2025, according to China's National Medical Products ...

A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...

In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...

Pharmaceutical Executive spoke with Lisa Bollinger, chief medical officer at Polaryx. The clinical-stage biotech focuses on ...